Drugs / S-588410
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02410369 Comparator | Mar 2015 → Mar 2020 | non-small cell lung carcinoma | Tokyo University | Unknown | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-16 | Shionogi | About a Phase III Clinical Study of Cancer-Specific Peptide Vaccine S-588410 in Patients with Esophageal Cancer shionogi.com ↗ |
| 2018-12-21 | OncoTherapy Science, Inc. | がん特異的ペプチドワクチン S-588410 第Ⅲ相臨床試験進捗に伴うマイルストーン受領のお知らせ oncotherapy.co.jp ↗ |
| 2018-03-05 | OncoTherapy Science, Inc. | がん特異的ペプチドワクチン S-588410 第Ⅲ相臨床試験進捗（最終患者登録）に関するお知らせ oncotherapy.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-588410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02410369 ↗ |
| Modality | Peptide | “S-588410 containing oncoantigens-derived HLA-A\*2402-restricted epitope peptides” NCT02410369 ↗ |
| Route | Subcutaneous | “will receive the subcutaneous administration of S-588410” NCT02410369 ↗ |